PhRMA says California pay-for-delay law should be struck down
( August 29, 2025, 23:31 GMT | Official Statement) -- MLex Summary: The Pharmaceutical Research and Manufacturers of America filed a brief in support of a US appeal court ruling against California’s pay-for-delay law. It argues that AB 824 directly conflicts with the federal patent laws by eroding core patent protections established by Congress and delays market entry, drives up litigation costs, deters development of new generics and biosimilars—and ultimately inflates prescription drug prices.See attached file. ...
Prepare for tomorrow’s regulatory change, today
MLex identifies risk to business wherever it emerges, with specialist reporters across the globe providing exclusive news and deep-dive analysis on the proposals, probes, enforcement actions and rulings that matter to your organization and clients, now and in the longer term.
Know what others in the room don’t, with features including:
- Daily newsletters for Antitrust, M&A, Trade, Data Privacy & Security, Technology, AI and more
- Custom alerts on specific filters including geographies, industries, topics and companies to suit your practice needs
- Predictive analysis from expert journalists across North America, the UK and Europe, Latin America and Asia-Pacific
- Curated case files bringing together news, analysis and source documents in a single timeline
Experience MLex today with a 14-day free trial.